default author photo

Jin Li

CanSino Biologics Inc.

SCHOLARLY PAPERS

1

DOWNLOADS

227

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b Trial

Number of pages: 25 Posted: 15 Feb 2023
Jundong Wu, Jing-Xin Li, Jian Liu, Haomeng Wang, Guanghui Zhou, Jin Li, Dou Wu, Xiang Chen, Yan Feng, Ying Wang, Xiaoyuan Qi, Xue Wang, Xiaomin Ma, Jin-Bo Gou, Tieliang Ma, Xiaoyun Yang, Lifeng Xu, Peng Wan, Tao Zhu, Zhongfang Wang and Feng-Cai Zhu
Yixing People's Hospital, Nanjing Medical University, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, Yixing People's Hospital, CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Laboratory, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Medical University - State Key Laboratory of Respiratory Disease and Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology
Downloads 227 (336,244)

Abstract:

Loading...

SARS-CoV-2, Omicron, heterologous booster, homologous booster, mRNA vaccine CS-2034, safety, immunogenicity